Travere reports preliminary Q4 rev ~$52M; sparsentan PDUFA Feb 17, 2023

Travere Therapeutics, Inc.

2022-FY EPS reported -$4.37 revenue$212,018,000

Preliminary net product sales Q4 2022 ~$52M; full year 2022 net product sales ~$201M, total revenue $212M.
Ended 2022 with ~$450M in cash, cash equivalents, and marketable securities.
FDA PDUFA for sparsentan in IgAN set for Feb 17, 2023; potential Q1 2023 launch if approved.
Phase 3 PROTECT (IgAN) topline confirmatory results expected Q4 2023; DUPLEX (FSGS) topline Q2 2023.
Phase 3 trial for pegtibatinase (HCU) to begin H2 2023; RESTORE study for CTX completion expected in 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Travere Therapeutics, Inc. reported the fourth quarter ended December 31, 2022 results: revenue approximately $52 million.

Period: the fourth quarter ended December 31, 2022
Revenue: approximately $52 million
Result: preliminary results

Exact text from the filing

the Company expects net product sales for the fourth quarter of 2022 to be approximately $52 million.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Travere Therapeutics, Inc. reported the fiscal year ended December 31, 2022 results: revenue $212 million.

Period: the fiscal year ended December 31, 2022
Revenue: $212 million
Result: preliminary results

Exact text from the filing

For the fiscal year 2022, the Company expects total revenue of $212 million, inclusive of approximately $201 million in net product sales and approximately $11 million in licensing and collaboration revenue.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Travere Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-004120

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.